1
Total investments
0
Early stage
0
Mid stage
0
Late stage
7y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Oct 2019
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
Experience · 2 entries
All (2)
Investments (1)
Board (1)
2019
Board Member
Oct 2019
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
2006